Antipsoriatic effects of avarol-3′-thiosalicylate are mediated by inhibition of TNF-α generation and NF-αB activation in mouse skin

British Journal of Pharmacology

Volumn 152, Issue 3, 2007, Pages 353-365

  Amigo M ^a   Paya M ^a   De Rosa, S ^b   Terencio, M C ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Avarol 3 thiosalicylate; Inflammation; Keratinocyte; Monocyte; Mouse air pouch; Neutrophil; Nuclear factor B; Psoriasis; Tumour necrosis factor

Indexed keywords

1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 2 QUINOLONE; ANTIPSORIASIS AGENT; ARACHIDONIC ACID; AVAROL; AVAROL 3' THIOSALICYLATE; BIOLOGICAL MARKER; DEXAMETHASONE; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; LEUKOTRIENE B4; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; THIOSALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XANTHINE OXIDASE; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL INFILTRATION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA BINDING; DOSE RESPONSE; EDEMA; ENZYME ASSAY; EPIDERMIS HYPERPLASIA; FEMALE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INHIBITION KINETICS; KERATINOCYTE; LEUKOCYTE; MEDIATOR; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; SKIN; UPREGULATION;

ANIMALS; ANTIOXIDANTS; ARACHIDONIC ACID; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERPLASIA; INFLAMMATION MEDIATORS; KERATINOCYTES; MICE; MONOCYTES; NEUTROPHILS; NF-KAPPA B; OXIDATIVE STRESS; PROTEIN TRANSPORT; PSORIASIS; SALICYLIC ACIDS; SESQUITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848831226     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707394     Document Type: Article

References (69)

1. Afaq F, Saleem M, Krueger CG, Reed JD, Mukhtar H (2005). Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer 113: 423-433.
2. Amigó M, Terencio MC, Mitova M, Iodice C, Payá M, De Rosa S (2004). Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line. J Nat Prod 67: 1459-1463.
3. Andersen S, Sjursen W, Laegreid A, Volden G, Johansen B (1994). Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue. Inflammation 18: 1-12.
4. Anthonsen MW, Solhaug A, Johansen B (2001). Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha and interleukin-1beta-induced NF-kappa B activation. J Biol Chem 276: 30527-30536.
5. Arthur JS, Darragh J (2006). Signaling downstream of p38 in psoriasis. J Invest Dermatol 126: 1689-1691.
6. Asadullah K, Volk HD, Sterry W (2002). Novel immunotherapies for psoriasis. Trends Immunol 23: 47-53.
7. Banno T, Gazel A, Blumenberg M (2004). Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 279: 32633-32642.
8. Banno T, Gazel A, Blumenberg M (2005). Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 280: 18973-18980.
9. Bell S, Degitz K, Quirling M, Jilg N, Page S, Brand H (2002). Involvement of NF-κB signalling in skin physiology and disease. Cell Signalling 15: 1-7.
10. Betts WH (1985). Detecting oxy radicals by chemiluminescence. In: Greenwald R (eds). Handbook of Methods for Oxygen Radical Research. CRC Press: Boca Ratón, pp 197-201.
11. Borenfreund E, Babick H, Martin-Alguacil N (1988). Comparison of two in vitro cytotoxicity assays. The natural red (NR) and tetrazolium (MTT) test. Toxic In Vitro 2: 1-6.
12. Bos JD, De Rie MA, Teunissen MB, Piskin G (2005). Psoriasis: dysregulation of innate immunity. Br J Dermatol 152: 1098-1107.
13. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE (1988). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771.
14. Briganti S, Picardo M (2003). Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 17: 663-669.
15. Bustos G, Ferrándiz ML, Sanz MJ, Payá M, Alcaraz MJ (1995). A study of the novel anti-inflammatory agent florifenine topical antiinflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn Schmiedebergs Arch Pharmacol 351: 298-304.
16. Clark JD, Milona N, Knopf JL (1990). Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. Proc Natl Acad Sci USA 87: 7708-7712.
17. Courtois G (2005). The NF-kappaB signaling pathway in human genetic diseases. Cell Mol Life Sci 62: 1682-1691.
18. Cribier B (2006). Psoriasis under the microscope. J Eur Acad Dermatol Venereol 20: 3-9.
19. De Rosa S (2002). Mediterranean marine organisms as source of new potential drugs. In: Rauter AP et al. (eds). Natural Products in the New Millennium: Prospects and Industrial Application. Kluwer Academic Press: Dordrecht, pp 441-461.
20. De Vry CG, Valdez M, Lazarov M, Muhr E, Buelow R, Fong T et al. (2005). Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 125: 473-481.
21. Ferrándiz ML, Sanz MJ, Bustos G, Payá M, Alcaraz MJ, De Rosa S (1994). Avarol and avarone, two new anti-inflammatory agents of marine origin. Eur J Pharmacol 253: 75-82.
22. Franson R, Patriarca P, Elsbach P (1974). Phospholipid metabolism by phagocytic cells. Phospholipases A2 associated with rabbit polymorphonuclear leukocyte granules. J Lipid Res 15: 380-388.
23. Gaspari AA (2006). Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 54: S67-S80.
24. Gloire G, Legrand-Poels S, Piette J (2006). NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 30: 1493-1505.
25. Gottlieb AB (2005). Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 53: S3-S16.
26. Haas U, Podda M, Behne M, Gurrieri S, Alonso A, Furstenberg G et al. (2005). Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin. J Invest Dermatol 124: 204-211.
27. Haase I, Hobbs RM, Romero MR, Broad S, Watt FM (2001). A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. J Clin Invest 108: 527-536.
28. Han SS, Keum YS, Seo HJ, Chun KS, Lee SS, Surh YJ (2001). Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Lett 164: 119-126.
29. Ikai K (1999). Psoriasis and the arachidonic acid cascade. J Dermatol Sci 21: 135-146.
30. Johansen C, Flindt E, Kragballe K, Henningsen J, Westergaard M, Kristiansen K et al. (2005). Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 124: 1284-1292.
31. Kim HP, Imbert J, Leonard WJ (2006). Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 17: 349-366.
32. Kohler HB, Huchzermeyer B, Martin M, De Bruin A, Meier B, Nolte I (2001). TNF-alpha dependent NF-kappa B activation in cultured canine keratinocytes is partly mediated by reactive oxygen species. Vet Dermatol 12: 129-137.
33. Krueger JG (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1-23.
34. Lan CC, Yu HS, Wu CS, Kuo HY, Chai CY, Chen GS (2005). FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol 153: 725-732.
35. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V et al. (2005). Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 124: 1275-1283.
36. Lo CJ (2003). MAPK regulation of prostaglandin E2 production by lipopolysaccharide-stimulated macrophages is not dependent on nuclear factor kappaB. J Surg Res 113: 189-194.
37. Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H et al. (2004). Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem 47: 1930-1938.
38. Moroney MA, Alcaraz MJ, Forder RA, Carey F, Hoult JR (1988). Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J Pharm Pharmacol 40: 787-792.
39. Moustafa M, Szabo M, Ghanem GE, Morandini R, Kemp EH, MacNeil S et al. (2002). Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol 119: 1244-1253.
40. Mrowietz U, Asadullah K (2005). Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 11: 43-48.
41. Murakami M, Kudo I (2004). Secretory phospholipase A2. Biol Pharm Bull 27: 1158-1164.
42. Murakawa M, Yamaoka K, Tanaka Y, Fukuda Y (2006). Involvement of tumor necrosis factor (TNF)-alpha in phorbol ester 12-O-tetradecanoylphorbol-13- acetate (TPA)-induced skin edema in mice. Biochem Pharmacol 71: 1331-1336.
43. Nickoloff BJ, Nestle FO (2004). Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113: 1664-1675.
44. Norris DA (2005). Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 53: S17-S25.
45. Oberyszyn TM, Tober KL, Ross MS, Robertson FM (1998). Inhibitory effects of pentoxifylline on ultraviolet B light-induced cutaneous inflammation. Mol Carcinog 22: 16-25.
46. Okayama Y (2005). Oxidative stress in allergic and inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 4: 517-519.
47. Payá M, Halliwell B, Hoult JR (1992). Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. Biochem Pharmacol 44: 205-214.
48. Pennanen N, Lapinjoki S, Palander A, Urtti A, Monkkonen J (1995). Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion. Int J Immunopharmacol 17: 475-480.
49. Pittelkow MR (2005). Psoriasis: more than skin deep. Nat Med 11: 17-18.
50. Posadas I, Terencio MC, Guillen I, Ferrándiz ML, Coloma J, Payá M et al. (2000). Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol 361: 98-106.
51. Quivy V, Van Lint C (2004). Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 68: 1221-1229.
52. Reynolds NJ, McCombie SW, Shankar BB, Bishop WR, Fisher GJ (1997). SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13- acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin. Arch Dermatol Res 289: 540-546.
53. Rioja I, Terencio MC, Ubeda A, Molina P, Tarraga A, Gonzalez-Tejero A et al. (2002). A pyrroloquinazoline derivative with antiinflammatory and analgesic activity by dual inhibition of cyclooxygenase-2 and 5-lipoxygenase. Eur J Pharmacol 434: 177-185.
54. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F (2004). The inflammatory response in mild and in severe psoriasis. Br J Dermatol 150: 917-928.
55. Rys-Sikora KE, Konger RL, Schoggins JW, Malaviya R, Pentland AP (2000). Coordinate expression of secretory phospholipase A(2) and cyclooxygenase-2 in activated human keratinocytes. Am J Physiol Cell Physiol 278: C822-C833.
56. Rys-Sikora KE, Pentland AP, Konger RL (2003). Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes. J Invest Dermatol 120: 86-95.
57. Sato H, Nakayama Y, Yamashita C, Uno H (2004). Anti-inflammatory effects of tacalcitol (1,24(R)(OH)2D3, TV-02) in the skin of TPA-treated hairless mice. J Dermatol 31: 200-217.
58. Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y et al. (2002). New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs. J Med Chem 45: 930-936.
59. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards III CK (2004). Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol 13: 193-222.
60. Sipkema D, Osinga R, Schatton W, Mendola D, Tramper J, Wijffels RH (2005). Large-scale production of pharmaceuticals by marine sponges: sea, cell, or synthesis? Biotechnol Bioeng 90: 201-222.
61. Sjursen W, Brekke OL, Johansen B (2000). Secretory and cytosolic phospholipase A(2)regulate the long-term cytokine-induced eicosanoid production in human keratinocytes. Cytokine 12: 1189-1194.
62. Tak PP, Firestein GS (2001). NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
63. Tateson JE, Randall RW, Reynolds CH, Jackson WP, Bhattacherjee P, Salmon JA et al. (1988). Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol 94: 528-539.
64. Thommesen L, Sjursen W, Gasvik K, Hanssen W, Brekke OL, Skattebol L et al. (1998). Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1. J Immunol 161: 3421-3430.
65. Umezawa K, Chaicharoenpong C (2002). Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells 14: 163-167.
66. Victor FC, Gottlieb AB, Menter A (2003). Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 21: 392-397.
67. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR (2000). Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 275: 6259-6266.
68. Yamamoto Y, Gaynor RB (2001). Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142.
69. Yildirim M, Inaloz HS, Baysal V, Delibas N (2003). The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 17: 34-36.